Cadent Therapeutics, a Cambridge, Massachusetts-based, privately held clinical stage biopharmaceutical company focused on the development of therapies for the
Continue Reading Cadent Therapeutics Acquired by Novartis for Up to $770 Million

Aydin Harston combines his love for science and technology with legal expertise to advocate for his clients in all matters necessary to grow, protect, and defend their businesses. With a Ph.D. in biochemistry and numerous scientific and legal publications, Aydin seeks to produce creative and effective approaches to achieve his clients' goals as efficiently as possible.
Cadent Therapeutics, a Cambridge, Massachusetts-based, privately held clinical stage biopharmaceutical company focused on the development of therapies for the…
Continue Reading Cadent Therapeutics Acquired by Novartis for Up to $770 Million
Centripetal Networks, Inc. (“Centripetal”), one of the fastest growing innovators in the cybersecurity space, leveraged its patent portfolio against Cisco…
Continue Reading Lessons Learned From Centripetal’s Multi-Billion Dollar Damages Award Against Cisco
In the fast-paced and dynamic environment of startup and emerging companies, standard operating procedures and compliance matters may often fall…
Continue Reading Is it Time to Re-evaluate (or Create) Your Document Retention Policy?
On October 22, 2020, Boston-based Atea Pharmaceuticals, Inc. (“Atea”) announced an agreement with Roche for the exclusive rights to research,…
Continue Reading Atea Pharmaceuticals Collaborates with Roche on Oral COVID-19 Therapeutic
On October 7, 2020, Scribe Therapeutics announced a collaboration with Biogen, to collaborate on CRISPR-based medicines for treating neurological…
Continue Reading Scribe Enters CRISPR-Based Collaboration with Biogen
We use cookies to enhance your user experience. By continuing to use this site you are giving your consent for us to use cookies. For more information, please see our Privacy Policy.